187 related articles for article (PubMed ID: 35254695)
21. Disparities in direct acting antivirals uptake in HIV-hepatitis C co-infected populations in Canada.
Saeed S; Strumpf EC; Moodie EE; Young J; Nitulescu R; Cox J; Wong A; Walmsely S; Cooper C; Vachon ML; Martel-Laferriere V; Hull M; Conway B; Klein MB;
J Int AIDS Soc; 2017 Nov; 20(3):. PubMed ID: 29116684
[TBL] [Abstract][Full Text] [Related]
22. Impact of Removing Medicaid Fee-for-Service Hepatitis C Virus (HCV) Treatment Restrictions on HCV Provider Experience with Medicaid Managed Care Organizations in New York City.
Behrends CN; Gutkind S; Deming R; Fluegge KR; Bresnahan MP; Schackman BR
J Urban Health; 2021 Aug; 98(4):563-569. PubMed ID: 32016914
[TBL] [Abstract][Full Text] [Related]
23. Association of Medicaid Managed Care Drug Carve Outs With Hepatitis C Virus Prescription Use.
Auty SG; Shafer PR; Dusetzina SB; Griffith KN
JAMA Health Forum; 2021 Aug; 2(8):e212285. PubMed ID: 35977199
[TBL] [Abstract][Full Text] [Related]
24. Medicaid Subscription-Based Payment Models and Implications for Access to Hepatitis C Medications.
Auty SG; Shafer PR; Griffith KN
JAMA Health Forum; 2021 Aug; 2(8):e212291. PubMed ID: 35977192
[TBL] [Abstract][Full Text] [Related]
25. Health care utilization and costs associated with direct-acting antivirals for patients with substance use disorders and chronic hepatitis C.
Jiang X; Vouri SM; Diaby V; Lo-Ciganic W; Parker R; Park H
J Manag Care Spec Pharm; 2021 Oct; 27(10):1388-1402. PubMed ID: 34595949
[No Abstract] [Full Text] [Related]
26. Hepatitis C virus elimination in Swiss opioid agonist therapy programmes - the SAMMSU cohort.
Bregenzer A; Bruggmann P; Castro E; Moriggia A; Rothen M; Thurnheer MC; Vernazza P; Scheidegger C
Swiss Med Wkly; 2021 Mar; 151():w20460. PubMed ID: 33705563
[TBL] [Abstract][Full Text] [Related]
27. Is the Availability of Direct-Acting Antivirals Associated with Increased Access to Hepatitis C Treatment for Homeless and Unstably Housed Veterans?
McInnes DK; Troszak LK; Fincke BG; Shwartz M; Midboe AM; Gifford AL; Dunlap S; Byrne T
J Gen Intern Med; 2022 Apr; 37(5):1038-1044. PubMed ID: 34173193
[TBL] [Abstract][Full Text] [Related]
28. Real-world treatment for chronic hepatitis C infection in Germany: Analyses from drug prescription data, 2010-2015.
Zimmermann R; Kollan C; Ingiliz P; Mauss S; Schmidt D; Bremer V
J Hepatol; 2017 Jul; 67(1):15-22. PubMed ID: 28189752
[TBL] [Abstract][Full Text] [Related]
29. Histopathology and the predominantly progressive, indeterminate and predominately regressive score in hepatitis C virus patients after direct-acting antivirals therapy.
Huang R; Rao HY; Yang M; Gao YH; Wang J; Jin Q; Ma DL; Wei L
World J Gastroenterol; 2021 Feb; 27(5):404-415. PubMed ID: 33584072
[TBL] [Abstract][Full Text] [Related]
30. Systematic review: economic evaluations of HCV screening in the direct-acting antivirals era.
Cortesi PA; Barca R; Giudicatti G; Mossini S; Ciaccio A; Iannazzo S; Micale M; Cesana G; Mantovani LG
Aliment Pharmacol Ther; 2019 May; 49(9):1126-1133. PubMed ID: 30843268
[TBL] [Abstract][Full Text] [Related]
31. Characteristics associated with time-to-treatment initiation for chronic Hepatitis C with new direct acting antivirals.
Karmarkar T; Padula WV; Gaskin DJ; Watson E; Rodriguez CV
Pharmacoepidemiol Drug Saf; 2021 Jan; 30(1):86-96. PubMed ID: 33090666
[TBL] [Abstract][Full Text] [Related]
32. Declining hepatitis C virus-related liver disease burden in the direct-acting antiviral therapy era in New South Wales, Australia.
Alavi M; Law MG; Valerio H; Grebely J; Amin J; Hajarizadeh B; Selvey C; George J; Dore GJ
J Hepatol; 2019 Aug; 71(2):281-288. PubMed ID: 31078544
[TBL] [Abstract][Full Text] [Related]
33. State Medicaid Reimbursement for Medications for Chronic Hepatitis C Infection from 2012 through 2015.
Lu CY; Zhang F; Golonski N; Lupton C; Jeffrey P; Wagner AK
Value Health; 2018 Jun; 21(6):692-697. PubMed ID: 29909874
[TBL] [Abstract][Full Text] [Related]
34. Barriers to the Treatment of Hepatitis C among Predominantly African American Patients Seeking Care in an Urban Teaching Hospital in Washington, D.C.
Liu L; Daftary MN; Alzahrani MS; Ohanele C; Maneno MK
J Natl Med Assoc; 2021 Apr; 113(2):147-157. PubMed ID: 32868101
[TBL] [Abstract][Full Text] [Related]
35. Evaluating hepatitis C cascade of care surveillance system in Tuscany, Italy, through a population retrospective data-linkage study, 2015-2021.
Ceccarelli L; Moretti G; Mazzilli S; Petri D; Corazza I; Rizzo C; Lucenteforte E; Vainieri M; Seghieri C; Tavoschi L;
BMC Infect Dis; 2024 Mar; 24(1):362. PubMed ID: 38553731
[TBL] [Abstract][Full Text] [Related]
36. Treating Hepatitis C in a Ryan White-Funded HIV Clinic: Has the Treatment Uptake Improved in the Interferon-Free Directly Active Antiviral Era?
Cope R; Glowa T; Faulds S; McMahon D; Prasad R
AIDS Patient Care STDS; 2016 Feb; 30(2):51-5. PubMed ID: 26744994
[TBL] [Abstract][Full Text] [Related]
37. Changing Urban-Rural Disparities in the Utilization of Direct-Acting Antiviral Agents for Hepatitis C in U.S. Medicare Patients, 2014-2017.
Du P; Wang X; Kong L; Riley T; Jung J
Am J Prev Med; 2021 Feb; 60(2):285-293. PubMed ID: 33221144
[TBL] [Abstract][Full Text] [Related]
38. Characteristics of Persons Treated for Hepatitis C Using National Pharmacy Claims Data, United States, 2014-2020.
Teshale EH; Roberts H; Gupta N; Jiles R
Clin Infect Dis; 2022 Sep; 75(6):1078-1080. PubMed ID: 35171997
[TBL] [Abstract][Full Text] [Related]
39. Do patients at high risk for Hepatitis C receive recommended testing? A retrospective cohort study of statewide Medicaid claims linked with OneFlorida clinical data.
Mkuu RS; Shenkman EA; Muller KE; Huo T; Salloum RG; Cabrera R; Zarrinpar A; Thomas E; Szurek SM; Nelson DR
Medicine (Baltimore); 2021 Dec; 100(50):e28316. PubMed ID: 34918711
[TBL] [Abstract][Full Text] [Related]
40. Race and Hepatitis C Care Continuum in an Underserved Birth Cohort.
Kim NJ; Locke CJ; Park H; Magee C; Bacchetti P; Khalili M
J Gen Intern Med; 2019 Oct; 34(10):2005-2013. PubMed ID: 30238404
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
